Harrow, Inc. has acquired the global rights to TYRVAYA nasal spray for $30 million in cash, with potential milestone payments of $70 million tied to future sales. This strategic acquisition enhances Harrow’s offerings in the dry eye disease market, attracting investor interest as shares have dropped 21% year-to-date.
Key Highlights
- Harrow, Inc. (NASDAQ: HROW) will acquire global rights to the TYRVAYA nasal spray for $30 million, with additional milestone payments totaling up to $70 million based on annual sales thresholds.
- Under the newly finalized Asset Purchase Agreement with Viatris Inc. Harrow will pay $30 million at closing, supplemented by the possibility of $70 million in contingent milestone payments.
- This acquisition aligns with Harrow's focus on expanding its portfolio in ophthalmic disease management.
Harrow, Inc. (NASDAQ: HROW) will acquire global rights to the TYRVAYA nasal spray for $30 million, with additional milestone payments totaling up to $70 million based on annual sales thresholds. This transaction represents a significant strategic move for the company, enhancing its existing dry eye portfolio to better address the growing demand for innovative treatments. With shares down 21% year-to-date, this acquisition offers a potential avenue for recovery and growth, capturing investors' attention in a slowing market.
Acquisition Details
Under the newly finalized Asset Purchase Agreement with Viatris Inc. Harrow will pay $30 million at closing, supplemented by the possibility of $70 million in contingent milestone payments. The deal encompasses TYRVAYA's related regulatory approvals, intellectual property, inventory, and certain liabilities. Harrow plans to use cash reserves for the initial payment while maintaining flexibility in its financial strategy.
The funding structure indicates a commitment to enhancing product offerings without jeopardizing liquidity, which is important given its recent financial performance that saw an EPS of $-0.74 against a $-0.41 consensus estimate for the quarter ending March 31, 2026.
Strategic Implications
This acquisition aligns with Harrow's focus on expanding its portfolio in ophthalmic disease management. TYRVAYA, as the first FDA-approved nasal spray for treating dry eye disease, complements Harrow's flagship VEVYE product. Both treatments will enhance patient options, particularly for those who cannot tolerate traditional eye drops.
As such, the potential synergies from cross-promotional opportunities may enhance sales efficiency and broaden the customer base. However, the company's continuing share price decline, with a loss of 14.6% over the past month, raises concerns about market confidence and the execution of this acquisition strategy.
Market Context
Harrow's recent market performance remains mixed, with peers like SEPN and TRLV observing modest gains of 0.6% and 0.9%, respectively. Investors are wary, reflecting an 18% short position of HROW shares, which translates into a coverage requirement of 12.6 days based on average trading volume. This indicates uncertainty within the market about Harrow's ability to effectively integrate and monetize TYRVAYA within its overall business strategy.
As Harrow aims to grow its portfolio, it must address these investor apprehensions, particularly in light of its recent volatility.
Future Catalysts
Harrow anticipates closing the acquisition transaction in the second half of 2026, contingent on fulfilling customary closing conditions. Investors will watch for updates related to this timeline, with particular attention to any indications of sales performance milestones that will trigger additional payments. The upcoming Q3 earnings report is scheduled to provide further insights into the company's financial health and strategic outlook as it integrates TYRVAYA into its offerings.
The team expects increased productivity and market presence through this expanded portfolio, but execution will be paramount for restoring investor confidence.
Peers Moving on This News
- Septerna Inc (SEPN) up 0.6%
- Trulieve Cannabis Corp (TRLV) up 0.9%
Analysis based on the Form 8-K filed 6 August 2026.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...